Filter by Category: In Vitro Activity

In-vitro activity of a combination of two oral β-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin.

In-vitro activity of a combination of two oral β-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin. by Johnson DM and Jones RN. published in J. Antimicrob. Chemother. 1998; 42 (4): 555-557

Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.

Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. by Doern GV, Jones RN, Pfaller MA, Erwin M and Ramirez-Rhonda C published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 113-119

In vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.

In vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp. by Croco MA, Biedenbach DJ, Pfaller MA, Doern GV, and Jones RN published in J. Antimicrob. Chemother. 1998; 42 (5): 672-673

In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.

In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates. by Cormican M, Corbett-Feeney G, Kelly S, Hughes D, Flynn J, and Jones RN published in Ir. J. Med. Sci. 1998; 167 (3): 155-159

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. by Jones RN, Barrett MS and Erwin ME published in Antimicrob. Agents Chemother. 1997; 41 (2): 488-493

Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: Analysis of the correlations between in vitro test results and clinical response.

Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: Analysis of the correlations between in vitro test results and clinical response. by Jones RN and Dudley MN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (1): 5-18

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. by Jamjian C, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (2): 454-459

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid® at 30:70 ratio) compared to alternative ratios for in vitro testing.

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid® at 30:70 ratio) compared to alternative ratios for in vitro testing. by Jamjian C, Barrett MS and Jones RN published in Diagn, Microbiol, Infect, Dis, 1997; 27 (4): 129-138

Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 Gram-negative bacteria.

Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 Gram-negative bacteria. by Gales AC, Pignatari AC, Jones RN, Baretta M and Sader HS published in Rev. Assoc. Med. Bras. 1997; 43 (2): 137-144

In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin.

In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin. by Erwin ME, Varnam D and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (2): 93-100